Ever-expanding landscape: Alzheimer’s—New targets and new patents
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
γ-secretase inhibitors such as tarenflurbil, avagacestat, and semagacestat lower amyloid beta synthesis by preventing gamma secretase enzyme from functioning.
“This includes γ-secretase inhibitors, such as tarenflurbil (7, Figure 5) [155,156], avagacestat (labeled as 6, Figure 5) [157,158], and semagacestat (5, Figure 5) [159,160]. Their purpose is to lower the synthesis of amyloid beta by preventing the gamma secretase enzyme from functioning.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [155]
Cites
Alzheimer’s disease: Recent treatment strategies
Vaz, M., & Silvestre, S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173554 · Cited by 547 · see citing works
New Approaches for the Treatment of Alzheimer’s Disease
Fish, P. V., Steadman, D., Bayle, E. D., & Whiting, P. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.11.034 · Cited by 189 · see citing works
Matěj, R., Tesař, A., & Rusina, R. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.08.005 · Cited by 158 · see citing works
Molecular and cellular pathophysiology of preclinical Alzheimer’s disease
Mufson, E. J., Ikonomović, M. D., Counts, S., Perez, S. E., Malek‐Ahmadi, M. H., Scheff, S. W., & Ginsberg, S. D. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.05.030 · Cited by 129 · see citing works
Kumar, N., Kumar, V., Anand, P., Kumar, V. V., Dwivedi, A. R., & Kumar, V. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116742 · Cited by 81 · see citing works
The molecular mechanism, targets, and novel molecules in the treatment of Alzheimer’s disease
Verma, A., Waiker, D. K., Bhardwaj, B., Saraf, P., & Shrivastava, S. K. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105562 · Cited by 58 · see citing works
Pradeepkiran, J. A., & Reddy, P. H. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166162 · Cited by 40 · see citing works
Swalley, S. E. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115239 · Cited by 24 · see citing works
Arbo, B. D., Ribeiro, M. F. M., & García‐Segura, L. M. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100943 · Cited by 15 · see citing works
Lee, H. E., Lim, D., Lee, J. Y., Lim, S. M., & Pae, A. N. (2019) · Pharmaceutical Patent Analyst · doi:10.4155/ppa-2019-0003 · Cited by 11 · see citing works
The Recent Pharmaceutical Patent Landscape for Alzheimer’s Disease: an Interview With Sang Min Lim
Lim, S. M. (2019) · Pharmaceutical Patent Analyst · doi:10.4155/ppa-2019-0022 · Cited by 2 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease
Thawabteh, A. M., Ghanem, A. W., AbuMadi, S., Thaher, D., Jaghama, W., Karaman, D., & Karaman, R. (2024) · Molecules · doi:10.3390/molecules29215131 · Cited by 56 · see citing works
“This includes γ -secretase inhibitors, such as tarenflurbil ( 7 , Figure 5) [155,156], avagacestat (labeled as 6 , Figure 5) [157,158], and semagacestat ( 5 , Figure 5) [159,160].”
Background
- Authors
- Egunlusi, A. O., & Joubert, J.
- Affiliations
- University of the Western Cape (ZA)
- Venue
- Pharmaceutical Patent Analyst
- Publisher
- Informa UK Limited
- Published
- 2022-09
- Volume
- 11
- Issue
- 5
- Pages
- 135-138
- ISSN
- 2046-8954 (ISSN-L)
- 2046-8962
- OpenAlex
- W4294224626
- Cited by
- 1
- References
- 11
- Citations by year
- 2024: 1
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pharmaceutical Patent Analyst (publishedVersion)
- PubMed (publishedVersion)
- Funders
- South African Medical Research Council (SAMRC RCDI-Nested Postdoctoral Scholarship)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
- Social Sciences › Business, Management and Accounting › Management of Technology and Innovation › Intellectual Property and Patents
- Keywords
- Alzheimer's disease, therapeutic target, pharmaceutical patents, patent landscape
- MeSH terms
- Alzheimer Disease, Humans, Amyloid beta-Peptides, tau Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
